Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
Biocon Limited Press Release Sep 21 2026
Earlier from Biocon
- Biocon Limited Press Release Sep 08 2026
- Biocon Announces Supplemental U.S. FDA Approval For Prefilled Autoinjector For YESINTEK
- Biocon Launches Aflibercept Biosimilar In The United States
- Biocon Limited Press Release Aug 05 2026